ADMA Biologics (ADMA) said Monday it doesn't expect the latest US tariffs on foreign goods and services to have any impact on its supply chain or production operations.
The company's manufacturing operations, end-market sales, and customer engagements are all conducted exclusively within the US, Chief Executive Adam Grossman said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.